Last reviewed · How we verify
Cablivi
Cablivi, developed by the University of Cologne, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Cablivi |
|---|---|
| Sponsor | University of Cologne |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| Annual revenue | 400 |
Approved indications
Common side effects
Key clinical trials
- Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (PHASE3)
- Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
- Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
- Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cablivi CI brief — competitive landscape report
- Cablivi updates RSS · CI watch RSS
- University of Cologne portfolio CI